SOW
HRTX icon

State of Wyoming’s Heron Therapeutics HRTX Stock Holding History

State of Wyoming’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.5K Sell
50,618
-8,006
-14% -$9.28K ﹤0.01% 1575
2025
Q4 		$76.2K Buy
+58,624
New +$72.4K 0.01% 1373
2025
Q1 		– Sell
-29,736
Closed -$45.5K – 1735
2024
Q4 		$45.5K Buy
29,736
+25,321
+574% +$41K 0.01% 1459
2024
Q3 		$8.79K Sell
4,415
-28,312
-87% -$67.6K ﹤0.01% 1616
2024
Q2 		$115K Sell
32,727
-23,347
-42% -$71.7K 0.02% 942
2024
Q1 		$155K Sell
56,074
-30,088
-35% -$75.6K 0.03% 753
2023
Q4 		$146K Buy
86,162
+63,511
+280% +$69.9K 0.03% 758
2023
Q3 		$23.3K Sell
22,651
-1,373
-6% -$1.95K 0.01% 1488
2023
Q2 		$27.9K Buy
+24,024
New +$42.8K 0.01% 1341
2022
Q2 		– Sell
-525
Closed -$3K – 1991
2022
Q1 		$3K Buy
525
+88
+20% +$644 ﹤0.01% 1683
2021
Q4 		$4K Sell
437
-23
-5% -$235 ﹤0.01% 1735
2021
Q3 		$5K Sell
460
-43
-9% -$524 ﹤0.01% 1087
2021
Q2 		$8K Buy
503
+267
+113% +$4.25K 0.01% 1036
2021
Q1 		$4K Buy
+236
New +$4.21K 0.01% 447

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

State of Wyoming's HRTX Position: Q1 2026 in Review

State of Wyoming reduced its Heron Therapeutics (HRTX) stake by 14% in Q1 2026, selling an estimated $9.28K and leaving 50,618 shares worth $40.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1575.

State of Wyoming first reported a position in HRTX in Q1 2021 and has held it in 14 quarters since. The position peaked at $155K in Q1 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • State of Wyoming held 50,618 shares of Heron Therapeutics worth $40.5K as of Q1 2026.
  • State of Wyoming sold 8,006 Heron Therapeutics shares in Q1 2026, an estimated $9.28K.
  • Heron Therapeutics made up ﹤0.01% of State of Wyoming's portfolio in Q1 2026, its #1575 holding.
  • State of Wyoming first reported a position in Heron Therapeutics in Q1 2021 and has held it in 14 quarters since.
  • State of Wyoming's Heron Therapeutics position peaked at $155K in Q1 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on State of Wyoming's 13F filing for Q1 2026, filed 13 May 2026.